IN8bio, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. It is conducting two investigator-initiated Phase 1 clinical product candidates comprising INB-200, a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors; and INB-100, an allogeneic product candidate for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was founded in 2016 and is based in New York, New York.